Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression

Journal of Infectious Diseases

Volumn 186, Issue 8, 2002, Pages 1086-1091

  Phillips, Andrew N ^a,b   Staszewski, Schlomo ^c,i   Lampe, Fiona ^a,b   Youle, Michael S ^a   Klauke, Stephan ^c,i   Bickel, Markus ^c,i   Sabin, Caroline A ^a,b   Doerr, Hans Wilhelm ^c,i   Johnson, Margaret A ^a   Loveday, Clive ^a,g   Miller, Veronica ^c,d   Phillips, Andrew ^a   Sabin, Caroline ^a   Mocroft, Amanda ^a   Moore, Antonia ^a   Cozzi Lepri, Alessandro ^a   Paddam, Lucy ^a   Smith, Colette ^a   Chaloner, Clinton ^a   Johnson, Margaret ^a   Lipman, Marc ^a   Youle, Mike ^a   Barry, Simon ^a   Drinkwater, Tony ^a   Madge, Sara ^a   Mitchla, Zuber ^a   Tyrer, Mervyn ^a   Lee, Christine ^e   Thynn Yee, Thynn ^e   Janossy, George ^a   Kinloch de Loes, Sabine ^a   Jacobs, Mike ^a   Zumla, Ali ^a   Gillespie, Stephen ^a   Sherr, Lorraine ^f   Bolding, Graham ^f   Griffiths, Paul ^h   Emery, Vince ^h   Deayton , Jane ^h   Carlebach, Amina ⁱ   Dauer, Brenda ⁱ   Gute, Peter ⁱ   Haberl, Annette ⁱ   Helm, Eilke B ⁱ   Locher, Leo ⁱ   Lutz, Thomas ⁱ   Moösch, Manfred ⁱ   Müller, Axel ⁱ   Stephan, Christof ⁱ   Stürmer, Martin ⁱ   more..

^a Royal Free Centre for HIV Medicine   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e Hemophilia   (United Kingdom)

^f Prevention and behavior change   (United Kingdom)

^g Retrovirology   (United Kingdom)

^h Virology Public Health Laboratory   (United Kingdom)

ⁱ Goethe Universitat Clinic Cohort   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0037108811     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/343801     Document Type: Article

References (15)

1. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
2. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160:1123-32.
3. Wit FWNM, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179:790-8.
4. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14:141-9.
5. Staszewski S, Miller V, Sabin CA, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13:367-73.
6. + cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr 2001; 27:161-7.
7. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12:2161-7.
8. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2661; 15:185-94.
9. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press, 1993.
10. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci 1997; 94:6971-6.
11. Phillips AN, Youle M, Johnson M, Loveday C. Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 2001; 15:2211-20.
12. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection-100-week follow-up. JAMA 1998; 280:35-41.
13. - T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
14. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at http://www.hivatis.org. Accessed 24 April 2002.
15. Phillips AN, Miller V. Sabin CA, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2661; 15:2379-84.